Healio
SearchLoading
Healio
SearchLoading

American Academy of Ophthalmology Meeting
ByMichael R. Robinson, MD

Read more

November 29, 2020
3 min watch
Save

VIDEO: Certain baseline characteristics predictive of Durysta duration of action

ByMichael R. Robinson, MD

In this Healio Video Perspective from the virtual AAO annual meeting, Michael R. Robinson, MD, discusses patient characteristics affecting long-term IOP-lowering effects after implantation of Durysta (bimatoprost intracameral implant, AbbVie).

Editor’s Note: This video was updated on Nov. 30 to correct the drug’s generic name.
Sources/Disclosures

Collapse
Source:

Khouri AS, et al. Predictive factors for long-term IOP lowering after bimatoprost implant 10-μg administration in phase 3 ARTEMIS studies. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting).

Read more from American Academy of Ophthalmology Meeting

View all

Read more about

open-angle glaucoma
bimatoprost
intraocular pressure
ocular hypertension
 

Related Content